Transgene S.A.
TNG
Classement en actions
#17814
Transgene SA, a French biotechnology firm headquartered in... Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Prix de l'action
$0.75803516
Capitalisation boursière
$210.93M
Changement (1 jour)
-6.29%
Changement (1 an)
-51.59%
Pays
FR
Échange Transgene S.A. (TNG)
Catégorie
Healthcare
Revenus pour Transgene S.A. (TNG)
Revenus en Oct 2026 TTM : 0
Selon les derniers rapports financiers de Transgene S.A., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Transgene S.A. de 2026 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
